Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Moderna lost more than $3 billion in maker value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Regulatory complexity isn’t the only challenges clinical services organizations face in the APAC market. Cheong points to ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

Every January, the Westin St. Francis in San Francisco is, for a few days, the center of the universe for the healthcare ...

Jan. 11, 2025 – Aug. 22, 2025 • New York, New York ...

Jan. 11, 2025 – Jan. 31, 2025 • new york, New York ...

Jan. 11, 2025 – Jan. 23, 2025 • New york, New York ...

She joins a team of experts at ON Partners, including partners Nina McMaster and Suzanne Zebedee, Ph.D., both recognized for ...

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...